奥曲肽联合血凝酶治疗急性肝硬化消化道出血患者的临床观察

Clinical observation of octreotide combined with hemagglutinin in treatment of patients with acute cirrhosis and gastrointestinal bleeding

目的探讨奥曲肽联合血凝酶治疗急性肝硬化消化道出血患者的临床意义。方法 80例急性肝硬化消化道出血患者,随机分为试验组和对照组,每组40例。所有入组患者均采取抗感染、卧床、静脉营养、抑酸、吸氧等方式治疗,在此基础上,对照组患者采用生长抑素治疗,试验组患者采用奥曲肽联合血凝酶治疗,比较两组患者临床治疗效果。结果试验组患者总有效率为95.0%,明显高于对照组的80.0%,差异具有统计学意义(P<0.05)。结论对急性肝硬化消化道出血患者采取奥曲肽联合血凝酶治疗,可以明显提高患者的临床治疗效果,值得在临床推广。

Objective To discuss the clinical significance of octreotide combined with hemagglutinin in treatment of patients with acute cirrhosis and gastrointestinal bleeding. Methods A total of 80 patients with acute cirrhosis and gastrointestinal bleeding were randomly divided into experimental group and control group, with 40 cases in each group. All the patients were treated with anti-infection, bedding, venous nutrition, acid suppression and oxygen absorption. The control group was treated with somatostatin, and the experimental group was treated with octreotide combined with hemagglutinin. The clinical treatment effect in two groups was compared. Results The experimental group had obviously higher total effective rate as 95.0% than 80.0% in the control group, and the difference was statistically significant（P〈0.05）. Conclusion Combination of octreotide and hemagglutinin can obviously improve the clinical effect of patients with acute cirrhosis and gastrointestinal bleeding, and it is worthy of clinical promotion.